Weight Change and the Risk of Chronic Pain Following Hip and Knee Arthroplasties

Sponsor
Bispebjerg Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06024161
Collaborator
(none)
6,400
13

Study Details

Study Description

Brief Summary

The study is a nationwide, register-based cohort survey study. The objective of this study is to investigate whether weight change is associated with the incidence of persistent postoperative pain following total hip arthroplasty and knee arthroplasty across non-obese and obese and patients.

Condition or Disease Intervention/Treatment Phase
  • Other: Weight gain
  • Other: Weight loss
  • Other: Weight unchanged

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
6400 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Weight Change and the Risk of Chronic Pain Following Hip and Knee Arthroplasties: A Nationwide Registry-based Cohort Survey Study.
Anticipated Study Start Date :
Nov 1, 2023
Anticipated Primary Completion Date :
Mar 31, 2024
Anticipated Study Completion Date :
Nov 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Weight gainers

Weight gain 11-15 months after arthroplasty

Other: Weight gain
≥5% weight gain

Weight losers

Weight loss11-15 months after arthroplasty

Other: Weight loss
≥5% weight loss after arthroplasty

Weight unchanged

Weight unchanged 11-15 months after arthroplasty

Other: Weight unchanged
<5% weight change after arthroplasty

Outcome Measures

Primary Outcome Measures

  1. Moderate/Severe Persistent Postoperative Pain [11-15 months postsurgically]

    The primary outcome is the number of patients with moderate or severe persistent postsurgical pain in the operated hip or knee, defined as patients with a numerical rating scale (NRS) score higher than 3. The outcome will be presented as Odd Ratio (OR) with its' corresponding 95% Confidence Interval (CI)

Secondary Outcome Measures

  1. Satisfaction [11-15 months postsurgically]

    Answering with "satisfied" or "very satisfied" in satisfaction question The outcome will be presented as Odd Ratio (OR) with its' corresponding 95% Confidence Interval (CI)

  2. Willingness to repeat the surgery [11-15 months postsurgically]

    Answering "yes" in willlingness question The outcome will be presented as Odd Ratio (OR) with its' corresponding 95% Confidence Interval (CI)

  3. Frequent pain [11-15 months postsurgically]

    Experiencing pain constantly, daily or few times a week The outcome will be presented as Odd Ratio (OR) with its' corresponding 95% Confidence Interval (CI)

  4. Use of analgaesic [11-15 months postsurgically]

    The outcome will be presented as Odd Ratio (OR) with its' corresponding 95% Confidence Interval (CI)

  5. Interference with daily activities [11-15 months postsurgically]

    Answering "some", "much" and "very much" in the interference question The outcome will be presented as Odd Ratio (OR) with its' corresponding 95% Confidence Interval (CI)

  6. WOMAC pain score [11-15 months postsurgically]

    mean (standard deviaiton [SD]). We will report the mean difference (MD) and the corresponding 95% CI

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Patients operated with primary hip or knee arthroplasty for osteoarthritis 11-15 months before survey distribution
Exclusion Criteria:
  • Legally incompetent citizens, i.e., persons with a legal guardian, will not be asked to participate.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Bispebjerg Hospital

Investigators

  • Study Director: Søren Overgaard, MD,DMSc,Prof, Department of orthopedic surgery, Bispebjerg University Hospital, Denmark

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Saber Muthanna Saber, MD, PhD fellow, Bispebjerg Hospital
ClinicalTrials.gov Identifier:
NCT06024161
Other Study ID Numbers:
  • p-2023-14578
First Posted:
Sep 6, 2023
Last Update Posted:
Sep 6, 2023
Last Verified:
Aug 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 6, 2023